CBER official overruled review team's rejection of new Replimune melanoma drug

Asha Das, director of the FDA biologics center's office of clinical evaluation, overruled the agency's review team in granting an accelerated approval to Replimune's melanoma treatment Tudriqev in early August, new documents from the agency ...